CA3248093A1 - ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINES - Google Patents
ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINESInfo
- Publication number
- CA3248093A1 CA3248093A1 CA3248093A CA3248093A CA3248093A1 CA 3248093 A1 CA3248093 A1 CA 3248093A1 CA 3248093 A CA3248093 A CA 3248093A CA 3248093 A CA3248093 A CA 3248093A CA 3248093 A1 CA3248093 A1 CA 3248093A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- peptide
- vaccine composition
- amino acid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156006.3 | 2022-02-09 | ||
| EP22156007 | 2022-02-09 | ||
| EP22156007.1 | 2022-02-09 | ||
| EP22156006 | 2022-02-09 | ||
| PCT/EP2023/053259 WO2023152260A1 (en) | 2022-02-09 | 2023-02-09 | Anti-alpha-synuclein therapeutic vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3248093A1 true CA3248093A1 (en) | 2023-08-17 |
Family
ID=85175955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3248093A Pending CA3248093A1 (en) | 2022-02-09 | 2023-02-09 | ANTI-ALPHA-SYNUCLEIN THERAPEUTIC VACCINES |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250152684A1 (enExample) |
| EP (1) | EP4475878A1 (enExample) |
| JP (1) | JP2025506472A (enExample) |
| KR (1) | KR20240147981A (enExample) |
| AU (1) | AU2023219059A1 (enExample) |
| CA (1) | CA3248093A1 (enExample) |
| CL (1) | CL2024002370A1 (enExample) |
| CR (1) | CR20240371A (enExample) |
| IL (1) | IL314865A (enExample) |
| MX (1) | MX2024009485A (enExample) |
| WO (1) | WO2023152260A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024211543A1 (en) * | 2023-01-26 | 2025-07-17 | Ac Immune Sa | Liposomal construct |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| US12156912B2 (en) * | 2012-05-18 | 2024-12-03 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| RU2734924C2 (ru) | 2015-11-03 | 2020-10-26 | Аффирис Аг | Способ вакцинации против аутоантигена у пациента-человека |
| CN111787942B (zh) * | 2017-10-25 | 2024-03-29 | 杨森制药公司 | 磷酸化Tau肽的组合物及其用途 |
| AU2019253193B2 (en) * | 2018-04-10 | 2026-02-05 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| CA3185563A1 (en) * | 2020-08-04 | 2022-02-10 | Dorian WINTER | Immunogenic compounds |
-
2023
- 2023-02-09 KR KR1020247025028A patent/KR20240147981A/ko active Pending
- 2023-02-09 MX MX2024009485A patent/MX2024009485A/es unknown
- 2023-02-09 JP JP2024547294A patent/JP2025506472A/ja active Pending
- 2023-02-09 CA CA3248093A patent/CA3248093A1/en active Pending
- 2023-02-09 US US18/836,298 patent/US20250152684A1/en active Pending
- 2023-02-09 WO PCT/EP2023/053259 patent/WO2023152260A1/en not_active Ceased
- 2023-02-09 AU AU2023219059A patent/AU2023219059A1/en active Pending
- 2023-02-09 CR CR20240371A patent/CR20240371A/es unknown
- 2023-02-09 IL IL314865A patent/IL314865A/en unknown
- 2023-02-09 EP EP23703593.6A patent/EP4475878A1/en active Pending
-
2024
- 2024-08-07 CL CL2024002370A patent/CL2024002370A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023152260A1 (en) | 2023-08-17 |
| CR20240371A (es) | 2024-10-16 |
| AU2023219059A1 (en) | 2024-07-25 |
| JP2025506472A (ja) | 2025-03-11 |
| MX2024009485A (es) | 2024-08-14 |
| US20250152684A1 (en) | 2025-05-15 |
| CL2024002370A1 (es) | 2024-12-27 |
| KR20240147981A (ko) | 2024-10-10 |
| IL314865A (en) | 2024-10-01 |
| EP4475878A1 (en) | 2024-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250326806A1 (en) | Compositions of Phosphorylated Tau Peptides and Uses Thereof | |
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| US20230257433A1 (en) | Heterologous Administration of Tau Vaccines | |
| KR102869640B1 (ko) | 항-aveta 치료적 백신 | |
| US20250152684A1 (en) | Anti-Alpha-Synuclein Therapeutic Vaccines | |
| US20230287050A1 (en) | Immunogenic Compounds | |
| EA051687B1 (ru) | Терапевтические вакцины против альфа-синуклеина | |
| CN118660717A (zh) | 抗α-突触核蛋白的治疗性疫苗 | |
| HK40087814A (zh) | 免疫原性化合物 | |
| EA048154B1 (ru) | Иммуногенные соединения | |
| CN120583938A (zh) | 脂质体构建体 | |
| HK40105209A (zh) | 磷酸化tau肽的组合物及其用途 | |
| CN112165956A (zh) | 抗Aβ治疗性疫苗 | |
| HK40043189A (en) | Anti-abeta therapeutic vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240709 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241122 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241122 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241122 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241126 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250107 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260114 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260114 |